Radnet Inc(RDNT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.28 | Insider Own | 10.52% | Shs Outstand | 78.7M | Perf Week | 7.5% |
| Market Cap | 5.79B | Forward P/E | 82.17 | EPS next Y | 74.03% | Insider Trans | -0.62% | Shs Float | 70.4M | Perf Month | 4.09% |
| Enterprise Value | 7.54B | PEG | 1.97 | EPS next Q | 0.22 | Inst Own | 103.88% | Short Float | 12.87% | Perf Quarter | 17.31% |
| Income | -0.02B | P/S | 2.55 | EPS this Y | 31.87% | Inst Trans | 3.91% | Short Ratio | 13.27 | Perf Half Y | 31.58% |
| Sales | 2.27B | P/B | 5.28 | EPS next 5Y | 41.72% | ROA | -0.55% | Short Interest | 9.06M | Perf YTD | 3.07% |
| Book/sh | 13.94 | P/C | 7.97 | EPS past 3/5Y | - 3.18% | ROE | -2.08% | 52W High | -14.33% ($85.84) | Perf Year | -7.03% |
| Cash/sh | 9.23 | P/FCF | 79.97 | Sales past 3/5Y | 12.57% 13.74% | ROIC | -0.66% | 52W Low | 44.71% ($50.82) | Perf 3Y | 189.3% |
| Dividend Est. | - | EV/EBITDA | 27.32 | EPS Y/Y TTM | -37.55% | Gross Margin | 4.63% | Volatility(W/M) | 3.47% 3.3% | Perf 5Y | 137.3% |
| Dividend TTM | - | EV/Sales | 3.32 | Sales Y/Y TTM | 18.92% | Oper. Margin | 4.63% | ATR (14) | 2.4 | Perf 10Y | 973.58% |
| Dividend Ex-Date | - | Quick Ratio | 1.48 | EPS Q/Q | -50.05% | Profit Margin | -0.93% | RSI (14) | 58.25 | Recom | 1.11 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.48 | Sales Q/Q | 24.99% | SMA20 | 4.86% ($70.13) | Beta | 1.43 | Target Price | $94.62 |
| Payout | - | Debt/Eq | 1.99 | Earnings | 2026/8/9 | SMA50 | 1.2% ($72.67) | Rel Volume | 0.93 | Prev Close | $73.54 |
| Employees | 8844 | LT Debt/Eq | 1.9 | EPS/Sales Surpr. | 43.99% 1.94% | SMA200 | 12.89% ($65.14) | Avg Volume(3M) | 0.68M | Price | $73.54 |
| IPO | 1991/2/27 | Option/Short | Yes/Yes | Trades | 9793 | Volume | 633,214 | Change | - |
🩻 A healthcare company operating one of the largest outpatient imaging diagnostic networks in the United States. It runs outpatient imaging diagnostic centers offering services such as MRI (magnetic resonance imaging) and CT (computed tomography) scans, while also providing AI-based image analysis and early cancer screening solutions. The company is characterized by growth in both imaging diagnostic volume and AI solutions.
Over the past 1 year, roughly in the middle
14% below its 1-year high.
Traded about as much as usual. That is 93% of its average volume.
RDNT keeps an operating profit but posts a net loss
Of every $100 in sales, $4.63 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +31.9% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $255. Peers typically go for $458. Compared with its own 3-year average, it is 815% pricier now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +137.3%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 103.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #19 of 44 in the industry
Based on market cap of $6B.
FAQ
What kind of company is RDNT?
RDNT belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of RDNT?
The market cap of RDNT is approximately $5.8B, ranking 1,257 within its sector.
What is the 52-week high and low for RDNT?
RDNT has recorded a 52-week high of $85.84 and a low of $50.82.
